Recently it was also shown that in papillary thyroid carcinoma crizotinib acts as a antitumor agent by inhibiting phosphorylation of MET, AKT and its downstream signaling molecules and synergizes with TRAIL in suppression of tumor growth22. This evidence concerns the gene AKT1 and differentiated thyroid carcinoma.